BIO-key International Finalizes 1-for-10 Reverse Stock Split to Regain Nasdaq Compliance
Summary
BIO-key International, Inc. has finalized a 1-for-10 reverse stock split, effective April 29, 2026, to regain compliance with Nasdaq's minimum bid price requirement.
Key Events
-
Reverse Stock Split Finalized
The Board of Directors has set the reverse stock split ratio at 1-for-10, following stockholder approval on April 20, 2026.
-
Effective Date and Trading
The Certificate of Amendment becomes effective at 5:00 p.m. Eastern Time on April 29, 2026. Common Stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on April 30, 2026.
-
Share Reduction
The total outstanding shares of Common Stock will be reduced from approximately 10,852,118 to approximately 1,085,212 after the split.
-
Purpose for Nasdaq Compliance
The reverse stock split is intended to position the company for minimum bid price compliance with Nasdaq listing requirements.
Analysis
This filing confirms the implementation details of the reverse stock split previously approved by stockholders on April 20, 2026. The Board's decision to set the ratio at 1-for-10 is a critical step for BIO-key International to address its non-compliance with Nasdaq's minimum bid price requirement. While necessary for continued listing, reverse splits are generally viewed negatively by the market as they often signal underlying challenges with a company's stock performance, especially when trading near 52-week lows. Investors should monitor the stock's performance post-split and the company's ability to maintain compliance and execute on its growth goals.
At the time of this filing, BKYI was trading at $0.47 on NASDAQ in the Technology sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.46 to $1.97. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.